Skip to content
value.today
Bolt Biotherapeutics, Inc. logo

Bolt Biotherapeutics, Inc.

🇺🇸 Pleasanton, California, USABiotechnologyFounded 2015
Total raised
$178 M
6 rounds on record
Latest round
$15 M
Jun 2021
First round on record
Sep 2016
Today
Went public
See the company page

Bolt Biotherapeutics, Inc. is listed today as Bolt Biotherapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

6 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Bolt Biotherapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2021$15 MNo. 6$10 to $50 million

Bolt Biotherapeutics, Inc.: Raise no. 6, Jun 2021

Investors in this round

1 investor had bought by the notice of Jun 7, 2021: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Bolt Biotherapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$15 M of $15 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Dornan · Executive Officer
  • Edith Perez · Executive Officer
  • Grant Yonehiro · Executive Officer
  • Randall Schatzman · Executive Officer, Director
  • William Quinn · Executive Officer
  • Ashish Khanna · Director
  • Edgar Engleman · Director
  • James Healy · Director
  • Kathleen LaPorte · Director
  • Mahendra Shah · Director
  • Peter Moldt · Director
  • Richard Miller · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by William Quinn, Chief Financial Officer. Source: SEC Form D, newest notice filed Jun 7, 2021. Read the notice at the SEC.

equitySEC
Jun 2020$94 MNo. 5$50 to $250 million

Bolt Biotherapeutics, Inc.: Raise no. 5, Jun 2020

Investors in this round

17 investors had bought by the notice of Jan 28, 2021: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Bolt Biotherapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$94 M of $94 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Dornan · Executive Officer
  • Edith Perez · Executive Officer
  • Grant Yonehiro · Executive Officer
  • Randall Schatzman · Executive Officer, Director
  • William Quinn · Executive Officer
  • Ashish Khanna · Director
  • Edgar Engleman · Director
  • James Healy · Director
  • Kathleen LaPorte · Director
  • Mahendra Shah · Director
  • Richard Miller · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by William Quinn, Chief Financial Officer. Source: SEC Form D, newest notice filed Jan 28, 2021. Read the notice at the SEC.

equitySEC
Jul 2019$40 MNo. 4$10 to $50 million

Bolt Biotherapeutics, Inc.: Raise no. 4, Jul 2019

Investors in this round

11 investors had bought by the notice of Jul 15, 2019: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Bolt Biotherapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$40 M of $40 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Edgar Engleman · Executive Officer, Director
  • Grant Yonehiro · Executive Officer
  • Ashish Khanna · Director
  • Mahendra Shah · Director
  • Peter Moldt · Director
  • Richard Miller · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Grant Yonehiro, Chief Business Officer. Source: SEC Form D, newest notice filed Jul 15, 2019. Read the notice at the SEC.

equitySEC
Jul 2018$13 MNo. 3$10 to $50 million

Bolt Biotherapeutics, Inc.: Raise no. 3, Jul 2018

Investors in this round

11 investors had bought by the notice of Aug 6, 2018: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Bolt Biotherapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$13 M of $13 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Grant G. Yonehiro · Executive Officer
  • Ashish G. Khanna · Director
  • Edgar G. Engleman · Director
  • Mahendra G. Shah · Director
  • Peter G. Moldt · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Grant Yonehiro, Chief Business Officer. Source: SEC Form D, newest notice filed Aug 6, 2018. Read the notice at the SEC.

equitySEC
Feb 2018$6 MNo. 2$2 to $10 million

Bolt Biotherapeutics, Inc.: Raise no. 2, Feb 2018

Investors in this round

6 investors had bought by the notice of Feb 20, 2018: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Bolt Biotherapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Edgar G. Engleman · Executive Officer, Director
  • Grant G. Yonehiro · Executive Officer
  • Ken G. Harrison · Director
  • Mahendra G. Shah · Director
  • Peter G. Moldt · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Grant Yonehiro, Chief Business Officer. Source: SEC Form D, newest notice filed Feb 20, 2018. Read the notice at the SEC.

equitySEC
Sep 2016$10 MNo. 1$10 to $50 million

Bolt Biotherapeutics, Inc.: Raise no. 1, Sep 2016

Investors in this round

6 investors had bought by the notice of Sep 30, 2016: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Bolt Biotherapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$10 M of $16 M offered; $6 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Edgar G. Engleman · Executive Officer, Director
  • Reiner Laus · Executive Officer, Director
  • Mahendra G. Shah · Director
  • Peter G. Bisgaard · Director
  • Peter G. Moldt · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Reiner Laus, President and CEO. Source: SEC Form D, newest notice filed Sep 30, 2016. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Bolt Biotherapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2021).

    SEC Form D · Jun 2021

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jun 2021

That is all the official record says: Bolt Biotherapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Bolt Biotherapeutics, Inc. are on record.

Investors#

8 named in official filings. Open an investor to see everything it has backed.

Investors in Bolt Biotherapeutics, Inc.
InvestorKindAmountRoundRoleSource
Novo Holdings A/sFund or asset managernot statednot statedHeld Series A-1, B, C-1 and C-2 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Sofinnova Management X, L.L.C.Fund or asset managernot statednot statedHeld Series C-1 and C-2 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Sofinnova Venture Partners X, L.P.Venture capitalnot statednot statedHeld Series C-1 and C-2 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Vivo Capital Fund VIII, L.P.Fund or asset managernot statednot statedHeld Series A-1, B, C-1 and C-2 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Vivo Capital Surplus Fund VIII, L.P.Fund or asset managernot statednot statedHeld Series A-1, B, C-1 and C-2 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Vivo Capital VIII, LLCFund or asset managernot statednot statedHeld Series A-1, B, C-1 and C-2 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Vivo Panda Fund, L.P.Fund or asset managernot statednot statedHeld Series A-1, B, C-1 and C-2 preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Vivo Panda, LLCOthernot statednot statedHeld Series A-1, B, C-1 and C-2 preferred stock, 10% owner (Form 3, 2021)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 6 rounds above had up to 17 investors.

Largest shareholders today

Institutions holding Bolt Biotherapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Bolt Biotherapeutics, Inc.
NameRoleNamed in
David DornanExecutive officerJun 2021
Edith PerezExecutive officerJun 2021
Grant YonehiroExecutive officerJun 2021
Randall SchatzmanExecutive officerJun 2021
William QuinnExecutive officerJun 2021
Edgar EnglemanExecutive officerJul 2019
Grant G. YonehiroExecutive officerAug 2018
Edgar G. EnglemanExecutive officerFeb 2018
Reiner LausExecutive officerSep 2016
Ashish KhannaDirectorJun 2021
Edgar EnglemanDirectorJun 2021
James HealyDirectorJun 2021
Kathleen LaPorteDirectorJun 2021
Mahendra ShahDirectorJun 2021
Peter MoldtDirectorJun 2021
Randall SchatzmanDirectorJun 2021
Richard MillerDirectorJun 2021
Ashish G. KhannaDirectorAug 2018
Edgar G. EnglemanDirectorAug 2018
Mahendra G. ShahDirectorAug 2018
Peter G. MoldtDirectorAug 2018
Ken G. HarrisonDirectorFeb 2018
Peter G. BisgaardDirectorSep 2016
Reiner LausDirectorSep 2016

Went public since 2021. Its SEC number is that of a company listed on a stock exchange.